Research Project
9680061
PROJECT SUMMARY Dravet Syndrome (DS) is one of the most pharmacoresistant epilepsy syndromes. In ~80% of patients, DS results from loss-of-function mutations in the Scn1a gene which encodes brain voltage-gated sodium channel type-I, NaV1.1. Effective therapy for DS is extremely limited. The current first-line therapy for DS is a combination of Onfi® (clobazam) and valproic acid. Stiripentol (STP) is often added for pharmacoresistant patients but is not an FDA approved treatment. Unfortunately, this combination not only fails to provide complete seizure control, but also causes serious adverse events in over 50% of patients. Better therapeutic strategies are urgently needed. Encouragingly, recent discoveries have unearthed a promising new pathway for treating this terrible disease. Animal studies in Scn1a+/- heterozygous knockout mice (a well-established animal model of DS) have established that spontaneous seizures, hyperthermia-induced seizures, and high rates of premature death are associated with reduced Gabra2 expression in the forebrain. Gabra2 encodes the production of the ?2 protein subunit of GABAAR. Intriguingly, clobazam and its metabolite, N-desmethyl clobazam (NDMC), have modest selectivity in potentiating ?2-containing GABAARs. High doses of clobazam (10 mg/kg) eliminate hyperthermia- induced seizures in Scn1a+/- heterozygous knockout mice. This may partially explain why clobazam is effective in DS patients while other antiepileptics are not. STP not only increases NDMC levels through metabolic effects but is also selective for ?3-containing GABAARs. As a whole, this indicates that potentiating GABAARs containing ?2, and to a lesser extent ?3, may play a significant role in controlling seizures in DS patients. NeuroCycle Therapeutics, Inc. (NCT) specializes in the development of ?2/?3 subtype-selective GABAAR positive allosteric modulators. These compounds selectively potentiate ?2 and ?3 subtypes but have minimal effect on ?1 subtypes which are associated with side effects such as sedation, dependency, ataxia, and tolerance development. If effective in DS models, these selective compounds could deliver next-generation treatment for DS that is effective, well-tolerated, and useable long-term. In preliminary studies, these compounds are equally or more efficacious than diazepam in multiple in vivo anticonvulsant models. They also show efficacy in treatment- refractory epileptic human cortical tissue. They display a significant margin of efficacy to side-effects, and do not lose efficacy upon chronic dosing. In this Phase I SBIR application, we propose to test two compounds with differentiated receptor profiles in two animal models of DS. Furthermore, we will perform a preliminary evaluation of these compounds' suitability as preclinical candidates. If Phase I objectives are met, we will apply to progress the best compound into a Phase II SBIR project, where additional pharmacology, toxicology, and pre-clinical development will occur.
